For over 30 years, Guthrie has been conducting cardiology clinical trials.   

Local access to leading-edge research

As a Guthrie patient you’ll have the unique opportunity to participate in clinical research trials that involve new treatments for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

Clinical trials

Clinical trials provide opportunities to evaluate the effectiveness of new ways to prevent, detect and treat cardiovascular disease. All FDA-approved medications and devices must prove effectiveness through a clinical trial.  Your individual participation will help advance new medical therapies for all patients. 

As a result, you receive excellent care locally from the Guthrie cardiology team, while still being able to access cutting-edge therapies offered in large university settings and metropolitan areas. Cardiology trials might involve preventive measures and/or treatments, experimental surgical techniques (stents), or devices (pacemakers, defibrillators), and/or new medicines. Your physician can present you with options and help you determine whether a clinical trial is right for you. 

Most clinical trials offered at Guthrie are phase two or phase three studies that measure safety and efficacy (whether the investigational treatment benefits a specific group of patients).

We work with multiple labs, pharmaceutical groups, and biotech companies to offer you the chance to get innovative treatments and novel therapies, and to assist with the future of cardiology care.  
 

Title: * Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07)

** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (Substudy Number: FH-PrwS-07-002)
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Flatiron Health, Inc.
Details (Identifier #): NCT06605404
Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Internal
Details (Identifier #): NCT05694338
Title: A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06568939
Title: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: Amgen Inc.
Details (Identifier #): 06745323
Title: A Phase 3 Randomized, Double-Blind, Active-Controlled
Study of Palazestrant with Ribociclib Versus Letrozole with
Ribociclib for the First-Line Treatment of ER+, HER2
Advanced Breast Cancer (OPERA-02)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT07085767
Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT06016738
Title: A Prospective, Multi-Center, Non-Randomized, SinGle-Arm Study of the BDTM Low ProfILe Vascular Covered Stent in PerIpheral ArTerY Disease (AGILITY)
Department: Vascular Surgery
Diagnosis: Vascular Disease
Principal Investigator:

Marica M.D., Silviu

Sponsors: Becton, Dickinson and Company
Details (Identifier #): NCT06111469
Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION:
THE RESTORATIVE303 STUDY
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator:

Srivatana MD, Ukorn

Sponsors: Vedanta Biosciences, Inc.
Details (Identifier #): NCT06237452
Title: A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Wang, Le

Sponsors: Shanghai Henlius Biotech, Inc.
Details (Identifier #): NCT06532006
Title: A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of
Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus
Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) – LIVIGNO-4
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06236438
Showing 1-10 of 41 Results